Walleye Capital
AGIO icon

Walleye Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Walleye Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,500
Closed -$60.2K – 4508
2025
Q3 		$60.2K Buy
+1,500
New +$56.4K ﹤0.01% 3936
2025
Q1 		– Sell
-4,000
Closed -$131K – 4177
2024
Q4 		$131K Hold
4,000
– – ﹤0.01% 4004
2024
Q3 		$178K Hold
4,000
– – ﹤0.01% 4087
2024
Q2 		$172K Sell
4,000
-6,800
-63% -$245K ﹤0.01% 4413
2024
Q1 		$316K Buy
10,800
+8,100
+300% +$217K ﹤0.01% 3621
2023
Q4 		$60.1K Buy
2,700
+600
+29% +$13.4K ﹤0.01% 4245
2023
Q3 		$52K Buy
+2,100
New +$55.5K ﹤0.01% 4184
2020
Q1 		– Sell
-14,400
Closed -$688K – 858
2019
Q4 		$688K Sell
14,400
-33,500
-70% -$1.27M 0.04% 544
2019
Q3 		$1.55M Buy
47,900
+34,600
+260% +$1.43M 0.09% 298
2019
Q2 		$663K Buy
13,300
+5,800
+77% +$310K 0.07% 391
2019
Q1 		$506K Buy
+7,500
New +$437K 0.08% 381

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Walleye Capital's AGIO Position: Q2 2025 in Review

Walleye Capital sold out of Agios Pharmaceuticals (AGIO) in Q2 2025, closing a stake of 150,511 shares — an estimated $4.41M sold.

Walleye Capital first reported a position in AGIO in Q1 2019 and held it in 9 quarters. The position peaked at $7.49M in Q4 2023. 214 funds tracked by Wall St. Rank hold AGIO as of Q2 2025.

  • Walleye Capital reported no remaining Agios Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 150,511 Agios Pharmaceuticals shares in Q2 2025, an estimated $4.41M.
  • Walleye Capital first reported a position in Agios Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Walleye Capital's Agios Pharmaceuticals position peaked at $7.49M in Q4 2023.
  • 214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.